University of Kentucky

UKnowledge
Internal Medicine Faculty Publications

Internal Medicine

6-2017

Lisinopril or Coreg CR in Reducing Cardiotoxicity in Women with
Breast Cancer Receiving Trastuzumab: A Rationale and Design of
a Randomized Clinical Trial
Maya Guglin
University of Kentucky, maya.guglin@uky.edu

Pamela Munster
University of San Francisco

Angelina Fink
University of South Florida

Jeffrey Krischer
University of South Florida

Follow this and additional works at: https://uknowledge.uky.edu/internalmedicine_facpub
Part of the Cardiology Commons, Clinical Trials Commons, and the Oncology Commons

Right click to open a feedback form in a new tab to let us know how this document benefits you.
Repository Citation
Guglin, Maya; Munster, Pamela; Fink, Angelina; and Krischer, Jeffrey, "Lisinopril or Coreg CR in Reducing
Cardiotoxicity in Women with Breast Cancer Receiving Trastuzumab: A Rationale and Design of a
Randomized Clinical Trial" (2017). Internal Medicine Faculty Publications. 175.
https://uknowledge.uky.edu/internalmedicine_facpub/175

This Article is brought to you for free and open access by the Internal Medicine at UKnowledge. It has been
accepted for inclusion in Internal Medicine Faculty Publications by an authorized administrator of UKnowledge. For
more information, please contact UKnowledge@lsv.uky.edu.

Lisinopril or Coreg CR in Reducing Cardiotoxicity in Women with Breast Cancer
Receiving Trastuzumab: A Rationale and Design of a Randomized Clinical Trial
Digital Object Identifier (DOI)
https://doi.org/10.1016/j.ahj.2017.03.010

Notes/Citation Information
Published in American Heart Journal, v. 188, p. 87-92.
© 2017 Elsevier Inc. All rights reserved.
This manuscript version is made available under the CC‐BY‐NC‐ND 4.0 license
https://creativecommons.org/licenses/by-nc-nd/4.0/.
The document available for download is the author's post-peer-review final draft of the article.

This article is available at UKnowledge: https://uknowledge.uky.edu/internalmedicine_facpub/175

HHS Public Access
Author manuscript
Author Manuscript

Am Heart J. Author manuscript; available in PMC 2018 June 01.
Published in final edited form as:
Am Heart J. 2017 June ; 188: 87–92. doi:10.1016/j.ahj.2017.03.010.

Lisinopril or Coreg CR in Reducing Cardiotoxicity in Women with
Breast Cancer Receiving Trastuzumab: a Rationale and Design
of a Randomized Clinical Trial
Maya Guglin1, Pamela Munster2, Angelina Fink3, and Jeffrey Krischer3

Author Manuscript

1University

of Kentucky, Lexington, KY

2University

of San Francisco, San Francisco, CA

3University

of South Florida, Tampa, FL

Abstract
Background—Trastuzumab (TZB) is an established therapy for HER2 positive breast cancer.
The use of TZB is commonly associated with cardiotoxicity manifesting as asymptomatic
decrease in left ventricular ejection fraction (LVEF) or overt heart failure. Several studies
demonstrated favorable effects of angiotensin converting enzyme (ACE) inhibitors and beta
blockers (BB) in the prevention of chemotherapy-induced cardiotoxicity. We hypothesize that
patients, randomized to receive an ACE inhibitor or a beta-blocker during trastuzumab therapy for
breast cancer, will maintain a higher LVEF than patients randomized to placebo.
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Methods and Results—We designed a prospective, multicenter, randomized, phase II placebocontrolled clinical trial to evaluate the effects of an ACE inhibitor (lisinopril) and a β-blocker
(carvedilol phosphate-extended release) on cardiotoxicity in patients with breast cancer who are
receiving adjuvant or neoadjuvant TZB therapy. The primary objectives include 1) comparison of
incidence of cardiotoxicity and 2) comparison of LVEF as a continuous variable in between the
arms. Cardiotoxicity was defined as an absolute decrease in LVEF from baseline of ≥ 10% at
follow-up or an absolute decrease of ≥ 5% in LVEF from baseline for individuals with < 50%
LVEF at follow-up.
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The target accrual is 468 participants, representing patients both with and without anthracycline
exposure. The enrollment is completed. The trial is co-sponsored by University of South Florida
and National Cancer Institute. The LVEF is being evaluated by echocardiography or multigated
acquisition scan.
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Conclusion—If we can demonstrate that the use of an ACE inhibitor or a BB can reduce the
degree of TZB-induced cardiotoxicity it is hoped that patients will receive complete and
uninterrupted TZB therapy for breast cancer without compromising cardiac function.
Clinical trial registration—SCUSF 0806 NCT01009918 (url https://clinicaltrials.gov/ct2/show/
NCT01009918).
Keywords
heart failure; chemotherapy-induced cardiotoxicity; cardio-oncology
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Human Epidermal Growth Factor receptor type 2 (HER2) is a type of transmembrane
tyrosine kinase receptor that normally regulates cell growth and survival, as well as
adhesion, migration, differentiation, and other cellular responses. It is overexpressed in 20–
30% of invasive breast carcinomas. HER2 positivity conveys a poor prognosis and decreased
overall survival as well as an altered response to anthracycline chemotherapeutic regimens.
Trastuzumab (Herceptin; Genentech, Inc.) is a recombinant humanized monoclonal antibody
that binds to the extracellular domain of the HER2 receptor. Use of trastuzumab (TZB) in
HER2 positive breast cancer became the greatest breakthrough therapy which reduces
mortality and dramatically improves disease-free survival. Pooled results from five
randomized trials of adjuvant trastuzumab showed a significant reduction of mortality (p <
0.00001), recurrence (p < 0.00001), metastases rates (p < 0.00001) and second tumors other
than breast cancer (p = 0.007) as compared to no adjuvant TZB patients 1.
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In 2001, Slamon et al reported 8.8 to 11% incidence of cardiotoxicity in patients receiving
paclitaxel and trastuzumab comparing to 1 to 4% in those who received paclitaxel alone, and
26 to 28% in those on trastuzumab and anthracyclines (AC) versus 6 to 9.6% on AC alone 2.
Multiple studies have been done since and have shown similar results 3–5. Most of the cases
of trastuzumab-induced cardiomyopathy are reversible, however, once trastuzumab is
discontinued, oncologists are frequently hesitant to re-expose patients to this agent.
Cardiotoxicity results in discontinuation of trastuzumab in up to 19% of patients 3. In our
retrospective study, 19.5% of patients permanently or temporarily discontinued TZB
secondary to cardiomyopathy 6.
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There are some reports, primarily from single center studies, demonstrating the protective
effects of angiotensine converting enzyme (ACE) inhibitors and beta blockers (BB) in
chemotherapy-induced cardiotoxicity. Specifically, Cardinale et al. 7 reported a 100%
prevention of AC-induced cardiomyopathy by enalapril, an ACE inhibitor. Similarly, Kalay
et al. 8 described a highly successful use of carvedilol, a BB, for prevention of
chemotherapy-associated cardiac toxicity. Based on these reports, as well as on our
preliminary data 6, we hypothesized that patients randomized to receive an ACE inhibitor or
a BB, simultaneously with initiation of TZB for HER2 positive breast cancer, would
preserve better cardiac function than those randomized to placebo. We defined cardiotoxicity
as decrease in LVEF of < 50% with a 5% drop from baseline, or a >10% decrease in ejection
fraction after initiating trastuzumab.
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Methods
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We designed a prospective, multicenter, randomized, phase II placebo-controlled clinical
trial evaluating the effects of an ACE inhibitor (lisinopril) and a β-blocker (carvedilol
phosphate-extended release) on cardiotoxicity in patients with breast cancer who are
receiving adjuvant or neoadjuvant TZB therapy. The primary objective of this study is to
determine if administration of lisinopril or carvedilol phosphate-ER, compared to placebo,
will reduce the incidence of trastuzumab-induced cardiotoxicity, as measured by LVEF, in
patients receiving adjuvant or neoadjuvant therapy for HER2 positive breast cancer. The
secondary objectives of this study are to: 1) determine whether participants on active agent
have fewer interruptions in TZB therapy due to cardiomyopathy, determine if treatment
effects are consistent in anthracycline and non-anthracycline cohorts, evaluate changes in
quality of life among the treatment groups during the study intervention, evaluate the long
term effects of the prevention of cardiomyopathy and impact on HRQL for either or both
active agents, and to compare the predictive value of Troponin I and BNP in the
identification of TZB cardiotoxicity.
We chose the extended release Coreg XR, rather than generic carvedilol, because, like
lisinopril, it is taken only once daily, and carvedilol has to be taken twice a day. A double
blind design of the study mandated a matching pattern of use of all the drugs in the trial.
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The trial is registered as SCUSF 0806 (SunCoast University of South Florida) and has a
ClinicalTrials.gov Identifier NCT01009918. The study described was supported by Award
Number U10CA081920 from the National Cancer Institute. Because the trial was designed
as a “real life” study, we allowed the participating centers to select their preferred imaging
modality. The LVEF is being evaluated by echocardiography or multigated acquisition scan,
depending on the preferences of the clinical investigators. To provide consistency within
centers, we required utilization of similar imaging modality throughout the follow-up, i.e. if
the patient had an echocardiogram at the baseline, subsequent images were also obtained by
echocardiography. Because we realize that multitude of the sites may provide inconsisted
readings, the Echo substudy was designed, where the analysis of sample echocardiograms is
being done by Duke core echocardiographic laboratory. Specifically, echocardiograms of all
patients meeting the definition of cardiotoxicity per their local sites, as well as their agematched controls without cardiotoxicity by local readers, were sent to the core laboratory.
The results will be reported separately from the main trial.
Definition of TZB-induced Cardiotoxicity
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TZB-induced cardiotoxicity usually manifests in decrease of left ventricular ejection fraction
(LVEF). There is no uniform definition of TZB –induced cardiotoxicity. When our trial was
being designed, the literature demonstrated high heterogeneity in the definitions 9. Examples
are shown in Table 1.
For SCUSF 0806 trial, we chose the definition of cardiotoxicity similar to Piccart-Gebhart et
al.10:
1.

A decrease in LVEF of ≥10% in patients whose LVEF is ≥50% or
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A drop in LVEF of at least 5% from baseline in patients whose LVEF decreases
to less than 50%.

Baseline LVEF must be measured within 6 weeks of study entry.
Subjects and Randomization

Author Manuscript

Subjects meeting the inclusion/exclusion criteria and giving informed consent are
randomized in a 1:1:1 ratio into the two treatment and control groups (lisinopril 10mg a day
versus Coreg XR 10mg versus placebo). The target enrollment is 468 patients at 128 centers.
The enrollment is completed. Half of the patients were exposed to anthracyclines prior to
trastuzumab therapy, while the other half was not. In terms of randomization, once a patient
consented to study, the site would call a toll free number and place the participant eligibility
out sources information into the automated system that would simultaneously enroll and
randomize the patient to study agent. The site pharmacy would receive and automated email
with a bottle number to dispense with the patients assigned blinded study agent.
Inclusion Criteria
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1.1

Women ≥ 18 years of age

1.2

HER2 positive breast cancer

1.3

Scheduled to receive adjuvant trastuzumab therapy

1.4

LVEF ≥ 50% by MUGA scan or echocardiogram, based on institutional/
clinician preference

1.5

Normal renal and hepatic function

1.6

Systolic blood pressure of > 90 mm Hg (sitting)

1.7

Pulse ≥ 60 beats/minutes

1.8

Able and willing to give informed consent

1.9

Signed HIPAA compliant research authorization to release Personal Health
Information to the SunCoast Research Base.

Exclusion criteria
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1.10

Prior treatment with trastuzumab

1.11

Current treatment with ACE inhibitors, BB or digoxin

1.12

Known cardiac history: heart failure, myocardial infarction, radiation-induced
cardiac dysfunction, clinically significant arrthymias, etc.

1.13

Known contraindication to either ACE inhibitors or BB

1.14

History of bronchial asthma or related bronchospastic conditions

1.15

Hereditary or idiopathic angioedema

1.16

Pregnant or breast feeding

1.17

Metastatic disease
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Study Procedures and Follow-up
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The study flow is summarized in Figure 1. Trastuzumab therapy was interrupted when the
subjects met the definition of cardiotoxicity. If the patient developed heart failure during the
study, trastuzumab was discontinued, study assignment unblinded, and further care provided
by local cardiologist in accordance with the guidelines. Nevertheless, follow-up visits take
place every three months, with documentation of the disease status, medical management,
LVEF, BNP & Troponin I; as well as QOL questionnaire at month 6 and 12.
Statistical Analyses

Author Manuscript

The primary aim of this study is to determine if treatment with lisinopril or carvedilol
phosphate ER results in reduction in incidence of trastuzumab-induced cardiotoxicity after
52 weeks of treatment as measured by preservation of LVEF, and comparison of the LVEF
of each treatment group with the placebo arm (where LVEF is a continuous variable). The
study is stratified according to whether patients received an anthracycline-containing
regimen or not to ensure balanced randomization.
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The study employs a two stage analysis plan. We will first compare each active agent arm
with the placebo arm. If a reduction effect is statistically significant in both agents (ACE and
BB), we will examine if there is any difference between the two study agents, recognizing
we do not have the same statistical power for this secondary analysis. If one or neither of the
active agent arms is statistically significantly different from the placebo arm, then the
secondary stage analysis will not be necessary. Kaplan-Meier survival curves will be
constructed to reflect time until event rates and the logrank statistic will be used to compare
them. Secondary end points will be addressed by using a Student-t test to compare the
changes of LVEF as a continuous measure between the two arms (treatment arms with
placebo) and a Pearson chi-square test will be used to compare the proportions of decreased
LVEF in each arm. For comparisons of each treatment with placebo, we will consider onesided 0.025 significant levels to adjust for the multiple testing. A mixed linear model will be
utilized to analyze the pattern of LVEF change during the course of this study using the data
from all follow-up visits. Furthermore, a proportional hazards model will be used to control
for potential confounders such as use of other cardiotoxic agents (i.e., AC).
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Quality of life changes will be evaluated using the European Organization for research and
Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ)-C30 V 3.0 at
baseline and at the end of treatment (end of trastuzumab therapy or week 52). The analysis
plan will utilize a linear regression model to consider the treatment effects on these
measurements (dependent variables) adjusted for age and other covariates to compare the
treatment arms. The observed data will be evaluated for normality and appropriate
transformation introduced prior to conducting the analysis. To assess the long term effect of
the study agents, follow-up measurements will be collected at study months 18 and 24 (or 6
and 12 months after the last dose of trastuzumab, if it was discontinued before week 52).
This exploratory analysis will be completed to determine the long term effects on the
prevention of cardiomyopathy and impact on QOL for either or both study agents. The
treatment groups will be compared to using appropriate two sample tests.
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Sample Size—The sample size calculation is based on the comparisons of each treatment
with placebo. Using a conservative incidence estimate, we hypothesize that 15% of women
treated for breast cancer with adjuvant trastuzumab will have decreased LVEF in the placebo
arm as compared to 5% of the women on the treatment arms. To detect a 10% difference in
women who exhibit a decrease in LVEF by the additional medication of lisinopril or
carvedilol, a sample size of 141 participants per arm is required to achieve 80% power for a
one sided test at the 0.025 significance level. Assuming a 10% drop-out rate, 468 subjects
were randomized to one of the three arms.
As possible, all statistical analyses will be based on the intent-to-treat principle. Subjects
will be analyzed according to their randomized assignment.
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Biomarkers: B-type natriuretic peptide and Troponin—B-type natriuretic peptide
(BNP) and Troponin are the biomarkers being checked regularly while participating on
study. The will be used in an effort try to identify patients at risk for cardiomyopathy before
they develop symptoms and before the drop of LVEF can be appreciated by
echocardiography or MUGA. Cardiac troponin I (TnI) may be a very reliable biomarker. In a
single center study by Cardinale et al. 7, only 5% of patients without TnI elevation in the
course of treatment developed cardiomyopathy. On the other hand, 62% of those with
elevated TnI later had reduced EF. Moreover, there was less recovery of cardiac function in
those patients who had elevated TnI. If this is confirmed in a randomized clinical trial like
the one we are doing now, the strategy may be changed from imaging patients every three
months which is cumbersome and costly to screening them with TnI first, and selectively
imaging only those in whom it is abnormal. There is no data on head to head comparison on
BNP and TnI. Receiver operating characteristic (ROC) curves will be used to determine the
value of these biomarkers in predicting trastuzumab-induced cardiotoxicity: The null
hypothesis is that areas under ROC (AUCROC) for the two biomarkers regarding
identification of trastuzumab induced cardiotoxicity (primary endpoint) are equal. The
AUCROC will be tested using Delong’s nonparametric approach, applying generalized Ustatistics to generate an estimated covariance matrix for correlated ROC curves. Due to the
uncertainty about the treatment effect of the active drugs, this analysis will be limited to the
placebo group only. With approximate 15% incidence rate in the placebo group, the
proposed sample size will achieve a power greater than 80% to reject the null if the true
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Safety management—Patients are monitored for adverse events attributable to study
agent at every study visit according to the Common Terminology Criteria for Adverse
Events (CTCAE) v4.0. All adverse events attributable to study agent were reported to the
SunCoast CCOP Research Base staff according to FDA guidelines. The study was also
reviewed for safety and progress by a Data Safety Monitoring Board every 6 months.

Discussion
This prospective randomized multicenter double blind placebo-controlled trial is the largest
study to address the prevention of TZB-induced cardiotoxicity. Unlike this study, most
similar studies addressing this important clinical issue are conducted in single centers, with
smaller sample size and less rigorous design 7, 8.
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The incidence of cardiomyopathy reported in individual clinical trials varies widely and
ranges from 7% 4 to 34% 11. In an overview of selected clinical trials on adjuvant breast
cancer treatment, Ewer et al.12 reported that overt clinical heart failure developed in < 4% of
patients, while asymptomatic decline in LVEF by 10 points was seen in ≤ 30% of patients.
Jones et al. report adverse cardiac effects in 5 of 28(17.9%), with two of them (3.8%)
symptomatic 13. Bhimaraj et al. 14 report cardiac dysfunction in 32%, including 14.3%
symptomatic, in their mixed adjuvant and metastatic patients. The University of Texas M.D.
Anderson Cancer Center (Houston, TX), observed cardiomyopathy in 28% of patients, with
a more stringent definition of EF decline; ≥ 20% from the baseline. There was also one
cardiac-related death (0.5%) 15. Our sample size calculation, based on the anticipated
cardiotoxicity rate of 15%, appears to be quite realistic.

Author Manuscript

In terms of clinical course of cardiac dysfunction which is secondary to TZB, it appears to
be mostly reversible. The MD Anderson Cancer center study, in which patients were referred
for suspected TZB-related cardiomyopathy, LVEF decreased from 61% +/− 13% at baseline
to 43% +/− 16% (p < 0.0001) after trastuzumab, and increased to 56% +/− 11% after the
discontinuation of therapy 16.
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Improvement in LVEF occurs after discontinuation of TZB, with cardiac medications or
without them, and re-exposure to TZB usually does not result in further decline in
LVEF 4, 15, 17. However, current protocols mandate discontinuation of TZB after LVEF
becomes abnormally low (<50%), and many women with breast cancer experience
interruptions in therapy 6. We designed our trial in an effort to prevent the development of
TZB-related cardiac dysfunction, using the medications that were reported to provide some
favorable effects, in a randomized, double blinded, placebo controlled population. Our
ultimate goal is to find the way to protect the heart and to avoid interruptions in the course of
TZB.
The trial is designed for community oncology groups rather than large institutions.
While the trial was in progress, results of two other randomized trials were published.
Although on a smaller scale, the two groups of investigators tried to answer similar question.
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In the Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research
(MANTICORE 101-Breast) trial, with a double-blinded, placebo-controlled design, patients
with HER2-positive breast cancer were randomly assigned to receive treatment with
perindopril, bisoprolol, or placebo (1:1:1, with 33, 31, and 30 patients, respectively) for the
duration of trastuzumab adjuvant therapy. After 17 cycles of trastuzumab, indexed left
ventricular end diastolic volume increased similarly in all patients, but trastuzumab-induced
decline in LVEF was attenuated in bisoprolol-treated patients (−1 ± 5%) relative to the
perindopril (−3 ± 4%) and placebo (−5 ± 5%) groups (P = .001). Perindopril and bisoprolol
use were independent predictors of maintained LVEF on multivariable analysis 18.
The second trial utilized angiotensin II antagonist candesartan for prevention of trastuzumab
related cardiotoxicity (defined as a decline in left ventricular ejection fraction (LVEF) of
more than 15% or a decrease below the absolute value 45%). in adjuvant setting. With a total
of 206 participants, randomized 1:1 into candesartan or placebo, the trial demonstrated no
Am Heart J. Author manuscript; available in PMC 2018 June 01.
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diffirence in the number of cardiac events between the groups. Moreover, candesartan did
not affect changes in NT-proBNP and troponin values 19.
The controversial results of these two studies underscores the timeliness of our trial.
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Table 1

Author Manuscript

Definitions of TZB-induced cardiotoxicity at the time of designing the current clinical trial
Author
Burstein

20
11

Year

N

Setting

Definition of cardiotoxicity

2001

40

Metastatic breast cancer

LVEF< 50% or decrease by 15%

2003

32

Metastatic breast cancer

LVEF<40% or decrease by >15%

Romond

3

2005

1159

Adjuvant

LVEF< 55% or decrease by >16%

Burstein

21

2003

54

Metastatic breast cancer

EF<40%

Bengala

13

2006

53

mixed

EF<50%

2005

850

Adjuvant

EF decrease by 10% to < 55%

2005

1677

Adjuvant

EF< 50% or decrease by 10%

Venturini 5

2006

45

Metastatic breast cancer

EF <45% or decrease by 20%

Guarneri 15

2006

173

Metastatic breast cancer

EF < 50% or decrease by 20%

Leyland-Jones

Tan-Chiu

22

Piccart-Gebhart

10
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